Primary CNS Lymphoma (PCNSL)
Oncology
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| epcoritamab | GH Research PLC (GHRS) |
Frequently asked questions
How many drugs are in development for Primary CNS Lymphoma (PCNSL)?
BioSniper tracks 1 drug in development for Primary CNS Lymphoma (PCNSL) across 1 company.
How many clinical trials target Primary CNS Lymphoma (PCNSL)?
There are 1 clinical trial targeting Primary CNS Lymphoma (PCNSL) tracked by BioSniper.
What is the prevalence of Primary CNS Lymphoma (PCNSL)?
The estimated prevalence of Primary CNS Lymphoma (PCNSL) is approximately 56.0 per 100,000 population.
Deep-dive into Primary CNS Lymphoma (PCNSL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis